Fig. 1. Anti-cancer efficacy of cetuximab in FaDu and FaDuCR cells.

a In vitro growth inhibition assay of cetuximab. FaDu or FaDuCR cells were treated with the indicated concentrations of cetuximab for 5 d. Cell viability was evaluated using the CellTiter-Glo assay and is shown relative to untreated control cells (mean ± SD of six independent experiments). b In a mouse FaDu or FaDuCR xenograft model, tumors were treated with cetuximab 40 mg kg⁻¹ or vehicle twice per week. Tumor growth curves are shown. Each group consisted of 10 mice. Data are mean ± SEM. c FaDu or FaDuCR cells were treated with 10 ng mL⁻¹ cetuximab for up to 48 h and probed for the indicated proteins. d In vitro growth inhibition assay of ipatasertib. FaDu or FaDuCR cells were treated with the indicated concentrations of ipatasertib for 5 d. Cell viability was evaluated using the CellTiter-Glo assay and is shown relative to untreated control cells (mean ± SD of six independent experiments). e FaDu or FaDuCR cells were treated with 3 µM ipatasertib for up to 48 h and probed for the indicated proteins